参考文献/References:
[1] WEINREB R N,KHAW P T.Primary open-angle glaucoma[J].Lancet,2004,363(9422):1711-1720.
[2] LIU Y Y,YU H.Effect of compound trabeculectomy on acute primary angle closure glaucoma under continuous high intraocular pressure state[J].J Xingxiang Med Coll,2015,32(2):160-162.
刘艳艳,余涵.原发性急性闭角型青光眼患者持续高眼压状态下行复合式小梁切除术疗效分析[J].新乡医学院学报,2015,32(2):160-162.
[3] LI X P,GAO J W,WANG S,LI Y,LIU J.Clinical effect of phacoemulsification combined with intraocular lens implantation in management of primary angle-closure glaucoma with cataract[J].J Xingxiang Med Coll,2015,32(2):169-170,174.
李晓鹏,高建伟,王爽,李彦,刘静.白内障超声乳化联合人工晶体植入术治疗 原发性青光眼合并白内障临床疗效观[J].新乡医学院学报,2015,32(2):169-170,174.
[4] HUANG P,ZHANG C.IL-4,IL-6 and IL-12 levels in patients with open-angle glaucoma[J].Rec Adv Ophthalmol,2005,25(1):41-42.
黄萍,张纯.开角型青光眼患者外周血中IL-4、IL-6、IL-12含量的研究[J].眼科新进展,2005,25(1):41-42.
[5] TEZEL G,WAX M B.The immune system and glaucoma[J].Curr Opin Ophthalmol,2004,15(2):80-84.
[6] WAX M B,YANG J,TEZEL G.Serum autoantibodies in patients with glaucoma[J].J Glaucoma,2001,10(5 Suppl):S22-24.
[7] WAX M,YANG J,TEZEL G.Autoantibodies in glaucoma[J].Curr Eye Res,2002,25(2):113-116.
[8] GRUS F H,JOACHIM S C,WUENSCHIG D,RIECK J,PFEIFFER N.Autoimmunity and glaucoma[J].J Glaucoma,2008,17(1):79-84.
[9] JONAS J B,GEORGE R,ASOKAN R,FLAXMAN S R,KEEFFE J,LEASHER J,et al.Prevalence and causes of vision loss in Central and South Asia:1990-2010[J].Br J Ophthalmol,2014,98(5):592-598.
[10] GE J,HE G M,ZHAO J L,FANG M,ELLWEIN L B,HE N,et al.Prevalence of blindness and moderate and severe visual impairment among adults aged 50 years or above in Yangxi County of Guangdong Province:the China Nine-Province Survey[J].Chin J Ophthalmol,2014,50(3):167-172.
葛坚,何光明,赵家良,方敏,ELLWEIN L B,何宁,等.我国九省眼病调查中广东省阳西县50岁及以上人群盲和中、重度视力损伤患病率及致病原因调查[J].中华眼科杂志,2014,50(3):167-172.
[11] LI W Y,HUANG P.Immunization and glaucoma[J].Chin J Exp Ophthalmol,2014,32(5):466-470.
李维义,黄萍.免疫与青光眼[J].中华实验眼科杂志,2014,32(5):466-470.
[12] BAKALASH S,KIPNIS J,YOLES E,SCHWARTZ M.Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent[J].Invest Ophthalmol Vis Sci,2002,43(8):2648-2653.
[13] HATA M,IKEDA H O,KIKKAWA C,IWAI S,MURAOKA Y,HASEQAWA T,et al.KUS121,a VCP modulator,attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress[J].Sci Rep,2017,7:44873.
[14] LEE K J,JEONG S M,HOEHN B D,HONG Y J,LEE S H.Valosin-containing protein is a novel autoantigen in patients with glaucoma[J].Optom Vis Sci,2011,88(1):164-172.
[15] PYE V E,DREVENY I,BRIGGS L C,SANDS C,BEURON F,ZHANG X,et al.Going through the motions:the ATPase cycle of p97[J].J Struct Biol,2006,156(1):12-28.
[16] BARBIN L,EISELE F,SANTT O,WOLF D H.The Cdc48-Ufd1-Npl4 complex is central in ubiquitin-proteasome triggered catabolite degradation of fructose-1,6-bisphosphatase[J].Biochem Biophys Res Commun,2010,394(2):335-341.
[17] DEICHSEL A,MOUYSSET J,HOPPE T.The ubiquitin-selective chaperone CDC-48/p97,a new player in DNA replication[J].Cell Cycle,2009,8(2):185-190.
[18] MEYER H,POPP O.Role(s) of Cdc48/p97 in mitosis[J].Biochem Soc Trans,2008,36(1):126-130.
[19] RAASI S,WOLF D H.Ubiquitin receptors and ERAD:a network of pathways to the proteasome[J].Semin Cell Dev Biol,2007,18(6):780-791.
[20] DAI R M,LI C C.Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation[J].Nat Cell Biol,2001,3(8):740-744.
[21] EGERTON M,ASHE O R,CHEN D,DRUKER B J,BURGESS W H,SAMELSON L E.VCP,the mammalian homolog of cdc48,is tyrosine phosphorylated in response to T cell antigen receptor activation[J].EMBO J,1992,11(10):3533-3540.
[22] BRAUN R J,ZISCHKA H.Mechanisms of Cdc48/VCP-mediated cell death:from yeast apoptosis to human disease[J].Biochim Biophys Acta,2008,1783(7):1418-1435.
[23] TEZEL G,SEIGEL G M,WAX M B.Autoantibodies to small heat shock proteins in glaucoma[J].Invest Ophthalmol Vis Sci,1998,39(12):2277-2287.
[24] WANG Y,VIRJI A S,HOWARD P,SAYANI Y,ZHANG J,ACHU P,et al.Detection of cleaved alpha-fodrin autoantigen in Sjgren’s syndrome:apoptosis and co-localisation of cleaved alpha-fodrin with activated caspase-3 and cleaved poly(ADP-ribose) polymerase (PARP) in labial salivary glands[J].Arch Oral Biol,2006,51(7):558-566.
[25] TAHZIB N G,RANSOM N L,REITSAMER H A,MCKINNON S J.Alpha-fodrin is cleaved by caspase-3 in a chronic ocular hypertensive (COH) rat model of glaucoma[J].Brain Res Bull,2004,62(6):491-495.
[26] ROHN T T,RISSMAN R A,DAVIS M C,KIM Y E,COTMAN C W,HEAD E.Caspase-9 activation and caspase cleavage of tau in the Alzheimer’s disease brain[J].Neurobiol Dis,2002,11(2):341-354.
[27] GRUS F H,JOACJIM S C,BRUNS K,LACKNER K J,PFEIFFER N,WAX M B.Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States[J].Invest Ophthalmol Vis Sci,2006,47(3):968-976.
[28] MCIIWAIN D R,BERGER T,MAK T W.Caspase functions in cell death and disease[J].Cold Spring Harb Perspect Biol,2013,5(4):a008656.
[29] NAKATSUMI H,YONEHARA S.Identification of functional regions defining different activity in caspase-3 and caspase-7 within cells[J].J Biol Chem,2010,285(33):25418-25425.
相似文献/References:
[1]李翔 谢钊 郭红建 谢学军 路雪婧 王毅 王超.补肾活血中药对大鼠慢性高眼压模型外侧膝状体病理改变的影响[J].眼科新进展,2012,32(1):000.
[2]范虹 刘五存 蔡鸿英 赵堪兴.改良二极管激光睫状体光凝术治疗中晚期青光眼[J].眼科新进展,2012,32(4):000.
[3]王建萍 赵燕麟 马勇 朱涛 程燕 车选义 赵桂娥 王柯.噻吗洛尔和布林佐胺联合曲伏前列素治疗原发性开角型青光眼与高眼压患者的临床研究[J].眼科新进展,2012,32(5):000.
[4]彭坤 靳隽 杨玉新 许银霞 王保君 闫义涛 杨华.长期联合应用噻吗洛尔对结膜组织炎性标记物ICAM-1和HLA-DR表达的影响[J].眼科新进展,2012,32(6):000.
[5]马恩普 赵小钊 董良 刘苏冰 曾照年.Healaflow在青光眼小梁切除术中的应用[J].眼科新进展,2012,32(6):000.
[6]王勇 叶应嘉 鲍先议 周龑丽 许荣 彭婷婷 曾志富.同轴微小切口超声乳化吸出术在青光眼滤过术后白内障摘出术中的应用[J].眼科新进展,2012,32(7):000.
[7]李翔 马世勇 李娟 王毅.补肾活血中药对大鼠慢性高眼压模型视神经病理改变的影响[J].眼科新进展,2013,33(2):000.
[8]白东娥 刘伟 季建.抗青光眼药物对青光眼患者泪液胰岛素水平的影响及其与眼表改变的关系[J].眼科新进展,2013,33(6):000.
[9]马英慧 张铁民 齐建平.原发性开角型青光眼与慢性原发性闭角型青光眼视网膜神经纤维层厚度与视野缺损的关系[J].眼科新进展,2013,33(7):000.
[10]张海涛 杨玉新 毛永 丁晓丽 秦海霞 梁长华 郭英昌.青光眼与非炎症性缺血型视神经病变的傅立叶OCT扫描视神经形态学对比[J].眼科新进展,2013,33(8):000.